Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - Harrison, S A; Bashir, M R; Guy, C D (Lancet, 2019)
(10213):